← Back to Clinical Trials
Recruiting NCT06341504

NCT06341504 Prevention Messages for EGMs: Effects on Behaviours and Cognitions

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06341504
Status Recruiting
Phase
Sponsor Benjamin Galipeau
Condition Gambling
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-02-27
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Prevention pop-up messagesMandatory time limitResponsible gambling information

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-02-27 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goals of this randomized controlled trial are to test the manifold effects of prevention pop-up messages on participants' behaviours, cognitions and affects. This study is conducted among regular EGMs' players (defined as having played EGMs at least once every two weeks for the past 12 months) who are not classified as probable pathological gamblers by the PGSI. After answering a series of short questionnaires by phone, participants are asked to schedule a gambling session which is done in a laboratory on the university's campus. This laboratory replicates a typical bar, and is equipped with real EGMs. Participants are recruited under the false pretense of giving their opinion on the realism of the bar replica, and on the overall feeling of the gambling session in it. They are told that: (a) they are free to gamble as much and for as long as they like; (b) they are allowed to take breaks; (c) gambling is to be done with their own money; (d) the only compensation for participation are the potential winnings made while gambling; (e) net winnings across their whole session are paid, but losses are real. There is only one participant at a time in the laboratory for the gambling session. After having stopped by their own volition (some exceptions apply, see "Detailed Description" for further details), participants are debriefed on the real goals of this study and reimbursed any incurred losses while gambling. They are then be asked to answer another series of questionnaires.

Eligibility Criteria

Inclusion Criteria: * At least 18 years old (legal age to gamble in Quebec, Canada, where the study is conducted) * Functional literacy in french (study is conducted in french and requires reading and understanding simple texts) * Having played EGMs and least once every two weeks for the past 12 months Exclusion Criteria: * Classified as a probable pathological gambler (score ≥ 8 on the PGSI) * Currently receiving treatment for problem gambling * Currently under self-exclusion from gambling venues

Contact & Investigator

Central Contact

CQEPTJ

✉ recrutementJEUX@psy.ulaval.ca

📞 1 866 677-5389

Principal Investigator

Benjamin Galipeau

PRINCIPAL INVESTIGATOR

Laval University

Frequently Asked Questions

Who can join the NCT06341504 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Gambling. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06341504 currently recruiting?

Yes, NCT06341504 is actively recruiting participants. Contact the research team at recrutementJEUX@psy.ulaval.ca for enrollment information.

Where is the NCT06341504 trial being conducted?

This trial is being conducted at Québec, Canada.

Who is sponsoring the NCT06341504 clinical trial?

NCT06341504 is sponsored by Benjamin Galipeau. The principal investigator is Benjamin Galipeau at Laval University. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology